Flagship Pioneering-founded Generate Biomedicines aims to offer less frequent injections compared to a blockbuster asthma drug from partners Amgen and AstraZeneca. Generate’s drug comes from a “programable biology” platform technology that uses AI and machine learning to design proteins with desirable properties.
The post Generate Biomedicines’ IPO Brings In $400M for Pivotal Tests of Severe Asthma Drug appeared first on MedCity News.
